Impact of a Pharmaceutical Interview at the Initiation of Opioid Treatment for Acute Non-cancer Pain

NCT07049796 | Completed

• 2 other identifiers: 2021/152/OBN° IDRCB : 2021-A01246-35
• Study Type: observational
• Target: 100
• Locations: 1 country
• Sites: 1

Brief Summary

In adult emergency departments, the number of admissions for adverse effects related to opioid use is constantly increasing. However, the massive flow of patients, lack of time, and rapid rotation of physicians in this department do not favor the transmission of in-depth information on the proper use of these therapies to the patient. In addition, this therapeutic class tends to worry patients. Public authorities as well as the medical profession are concerned about the potential adverse effects of morphine, but also the potential misuse, or even overdose, which can be fatal for the patient. Interventions by the community pharmacist in the fight against this misuse seem interesting, but an intervention upstream of potential problems of proper use seems even more relevant to us. Recent studies have shown the strong interest of the pharmacist in a multidisciplinary team on pain and opioids, both at the local level with studies conducted at the Rouen University Hospital by C. LATTARD et al. in rheumatology and E.BARAT et al. in outpatient surgery. It also appears that knowledge on the subject is satisfactory. Work conducted by Winstanley et al. shows that the intervention of a pharmacist in the emergency department seems relevant in terms of patient knowledge and satisfaction, and entirely feasible.

Conditions

Interviews

Keywords

Impact and feasibility of a pharmaceutical interview; opioid treatment

Outcome Measures

Primary Outcomes (1)

• Evaluation of satisfaction with a pharmaceutical interview for acute pain

  To assess satisfaction with pharmaceutical care for acute non-cancer pain in short-term hospitalization units (UHCD) and emergency downstream hospitalization units (UHA) during a telephone call to the patient 7 days after discharge from hospital. This satisfaction will be quantified as a percentage from 0 to 100%.

  Day 7

Secondary Outcomes (2)

• Evaluation of the relevance and effectiveness of pharmaceutical maintenance against pain

  Day 3

• Evaluation of the relevance and effectiveness of pharmaceutical maintenance against pain

  Day 3 and Day 7

Study Arms (1)

Prospective cohort including patients with opioid analgesic treatment upon discharge from hospital

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

Consecutive patients over 18 years of age with opioid analgesic treatment upon discharge from hospital

You may qualify if:

• Adult patient (\>18 years old)
• Patient admitted to the following departments: Downstream Hospitalization Unit (UHA) and Short-Term Hospitalization Unit (UHCD)
• Independent patient or assisted by close family (who can receive information with the patient)
• Initiation of opioid treatment for acute non-cancer pain during their stay in the Emergency Department, UHA, or UHCD or shortly before (\<7 days)
• Patient speaks French
• Presence of the clinical pharmacist in the relevant departments

You may not qualify if:

• Patient with drug addiction
• Patient under guardianship/guardianship
• Patient transferred to rheumatology
• Patient already on opioid treatment for ≥ 7 days
• Patient refuses
• Patient assisted by a nurse at home or a caregiver not present during hospitalization

Sponsors & Collaborators

• University Hospital, Rouen: lead

Study Sites (1)

University Rouen Hospital

Rouen, 76031, France

Location

MeSH Terms

Conditions

Tooth, Impacted

Condition Hierarchy (Ancestors)

Tooth Diseases; Stomatognathic Diseases

Study Officials

• Johanna JR RAYMOND, Doctor

  University Rouen Hospital

  STUDY DIRECTOR

Study Design

• Study Type: observational
• Observational Model: CASE ONLY
• Time Perspective: PROSPECTIVE
• Target Duration: 9 Days
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: June 25, 2025
• First Posted: July 3, 2025
• Study Start: October 12, 2021
• Primary Completion: November 30, 2024
• Study Completion: May 31, 2025
• Last Updated: July 3, 2025

Record last verified: 2025-01

Data Sharing

• IPD Sharing: Will not share

Locations

FR (1)